CD274 and metastatic melanoma: High baseline serum PD-1 or PD-L1 levels have been shown to predict poor PD-1 inhibition therapy outcomes in metastatic melanoma [33,34], indicating that the serum PD-L1 level may be used as a predictive marker assessing effects of anti-PD-1/PD-L1 therapies.